サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1239510

坐骨神経痛治療薬市場：タイプ別、薬物クラス別、流通チャネル別：世界の機会分析と産業予測、2021-2031年

Sciatica Treatment Market By Type, By Drug class, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日: | 発行: Allied Market Research | ページ情報: 英文 241 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
坐骨神経痛治療薬市場：タイプ別、薬物クラス別、流通チャネル別：世界の機会分析と産業予測、2021-2031年
出版日: 2023年01月01日
発行: Allied Market Research
ページ情報: 英文 241 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

坐骨神経痛治療薬の市場規模は、2021年に6億7,802万米ドルとなり、2022年から2031年にかけて3.9%のCAGRを示し、2031年には9億9,126万米ドルに達すると推定されています。

坐骨神経痛は、主に坐骨神経に影響を及ぼす痛みを指しますが、坐骨神経とは、腰から臀部、両脚を通る神経を指します。坐骨神経痛は通常、下半身の片側だけに起こりますが、腰からお尻、太ももやふくらはぎの裏まで、神経の通り道のどの部分にも痛みが出ることがあります。さらに、坐骨神経痛の一般的な症状として、座ると悪化する脚の痛み、脚の灼熱感やしびれ、立つのが困難なほどの痛みなどがあります。さらに、坐骨神経が侵された部分によっては、足や足の指にも痛みが出ることがあります。坐骨神経痛は、様々な薬や鎮痛剤を使って治療することができます。薬には、抗炎症薬、鎮痛薬、抗けいれん薬などがあります。

坐骨神経痛治療薬市場の成長を促進する主な要因は、坐骨神経痛の発生率の増加、坐骨神経痛の新規治療薬を開発するための研究開発活動の急増、坐骨神経痛とその治療に関する人々の意識の高まりです。発展途上国や先進国において、坐骨神経痛の発生率は増加しており、その原因はさまざまです。坐骨神経痛の主な原因は、椎間板ヘルニアやすべり症、椎間板変性症、脊柱管狭窄症、脊椎分離症などです。ジョンズ・ホプキンス関節炎センターによると、最近の人口推定では、米国における強直性脊椎炎（AS）の有病率は約0.2～0.5％、複数の国のデータに基づく年齢・性別調整後の発症率は10万人あたり0.4～14人であるとされているとのことで、強直性脊椎炎（AS）に対する関心が高まっています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • トップインパクトファクター
    • トップインベストメントポケット
  • ポーターのファイブフォース分析
    • 供給企業の交渉力の高さ
    • 買い手の適度な交渉力
    • 代替品の脅威は中程度です
    • 新規参入業者の脅威は中程度です
    • ライバルの強さは中程度
  • 市場力学
    • 促進要因
      • 坐骨神経痛の発症率の上昇
      • 老年人口の増加
      • 研究開発活動の増加
    • 抑制要因
      • 代替治療の有無
    • 機会
      • 新興国における成長機会
  • COVID-19市場への影響度分析

第4章 坐骨神経痛治療薬市場：タイプ別

  • 概要
    • 市場規模・予測
  • 急性坐骨神経痛
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • 慢性坐骨神経痛
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • その他
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析

第5章 坐骨神経痛治療薬市場：薬剤クラス別

  • 概要
    • 市場規模・予測
  • 非ステロイド性抗炎症薬
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • ステロイド
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • 抗うつ剤
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • その他
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析

第6章 坐骨神経痛治療薬市場：流通チャネル別

  • 概要
    • 市場規模・予測
  • 病院内薬局
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • 小売・専門薬局
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • オンラインプロバイダー
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析

第7章 坐骨神経痛治療薬市場：地域別

  • 概要
    • 市場規模・予測：地域別
  • 北米
    • 主な動向と機会
    • 市場規模・予測：タイプ別
    • 市場規模・予測：薬物クラス別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • 米国
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：タイプ別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • カナダ
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：タイプ別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • メキシコ
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：タイプ別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
  • 欧州
    • 主な動向と機会
    • 市場規模・予測：タイプ別
    • 市場規模・予測：薬物クラス別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • ドイツ
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：タイプ別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • フランス
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：タイプ別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • 英国
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：タイプ別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • イタリア
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：タイプ別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • スペイン
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：タイプ別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • その他欧州
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：タイプ別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
  • アジア太平洋地域
    • 主な動向と機会
    • 市場規模・予測：タイプ別
    • 市場規模・予測：薬物クラス別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • 日本
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：タイプ別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • 中国
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：タイプ別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • インド
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：タイプ別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • オーストラリア
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：タイプ別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • 韓国
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：タイプ別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • その他アジア太平洋地域
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：タイプ別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
  • LAMEA
    • 主な動向と機会
    • 市場規模・予測：タイプ別
    • 市場規模・予測：薬物クラス別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • ブラジル
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：タイプ別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • サウジアラビア
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：タイプ別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • 南アフリカ
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：タイプ別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • LAMEAの残りの地域
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：タイプ別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • トップ企業のポジショニング、2021年

第9章 企業プロファイル

  • Abbott Laboratories
  • Alkem Laboratories Ltd
  • Amneal Pharmaceuticals LLC
  • Johnson and Johnson
  • Sinfonia Biotherapeutics
  • Sorrento Therapeutics, Inc
  • Sun Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Limited
  • Teva Pharmaceutical Industries Limited
  • Aurobindo Pharma
図表

LIST OF TABLES

  • TABLE 01. GLOBAL SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 02. SCIATICA TREATMENT MARKET FOR ACUTE SCIATICA, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 03. SCIATICA TREATMENT MARKET FOR CHRONIC SCIATICA, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 04. SCIATICA TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 05. GLOBAL SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 06. SCIATICA TREATMENT MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 07. SCIATICA TREATMENT MARKET FOR STEROIDS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 08. SCIATICA TREATMENT MARKET FOR ANTIDEPRESSANTS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 09. SCIATICA TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. GLOBAL SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. SCIATICA TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. SCIATICA TREATMENT MARKET FOR RETAIL AND SPECIALTY PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. SCIATICA TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. SCIATICA TREATMENT MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. NORTH AMERICA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. NORTH AMERICA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. NORTH AMERICA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. NORTH AMERICA SCIATICA TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. U.S. SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. U.S. SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. U.S. SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. CANADA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. CANADA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. CANADA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. MEXICO SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. MEXICO SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. MEXICO SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. EUROPE SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. EUROPE SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. EUROPE SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. EUROPE SCIATICA TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. GERMANY SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. GERMANY SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. GERMANY SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. FRANCE SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. FRANCE SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. FRANCE SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. UK SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. UK SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. UK SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. ITALY SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. ITALY SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. ITALY SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. SPAIN SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. SPAIN SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. SPAIN SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. REST OF EUROPE SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. REST OF EUROPE SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. REST OF EUROPE SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. JAPAN SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. JAPAN SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. JAPAN SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. CHINA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. CHINA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. CHINA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. INDIA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. INDIA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. INDIA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. AUSTRALIA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. AUSTRALIA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. AUSTRALIA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. SOUTH KOREA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. SOUTH KOREA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. SOUTH KOREA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. LAMEA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. LAMEA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. LAMEA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. LAMEA SCIATICA TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. BRAZIL SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. BRAZIL SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. BRAZIL SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. SAUDI ARABIA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. SAUDI ARABIA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. SAUDI ARABIA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. SOUTH AFRICA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. SOUTH AFRICA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. SOUTH AFRICA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. REST OF LAMEA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. REST OF LAMEA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. REST OF LAMEA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 88. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 89. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 90. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 91. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 92. ABBOTT LABORATORIES: KEY STRATERGIES
  • TABLE 93. ALKEM LABORATORIES LTD: KEY EXECUTIVES
  • TABLE 94. ALKEM LABORATORIES LTD: COMPANY SNAPSHOT
  • TABLE 95. ALKEM LABORATORIES LTD: PRODUCT SEGMENTS
  • TABLE 96. ALKEM LABORATORIES LTD: PRODUCT PORTFOLIO
  • TABLE 97. ALKEM LABORATORIES LTD: KEY STRATERGIES
  • TABLE 98. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
  • TABLE 99. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 100. AMNEAL PHARMACEUTICALS LLC: PRODUCT SEGMENTS
  • TABLE 101. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
  • TABLE 102. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 103. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 104. JOHNSON AND JOHNSON: PRODUCT SEGMENTS
  • TABLE 105. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 106. SINFONIA BIOTHERAPEUTICS: KEY EXECUTIVES
  • TABLE 107. SINFONIA BIOTHERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 108. SINFONIA BIOTHERAPEUTICS: PRODUCT SEGMENTS
  • TABLE 109. SINFONIA BIOTHERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 110. SINFONIA BIOTHERAPEUTICS: KEY STRATERGIES
  • TABLE 111. SORRENTO THERAPEUTICS, INC: KEY EXECUTIVES
  • TABLE 112. SORRENTO THERAPEUTICS, INC: COMPANY SNAPSHOT
  • TABLE 113. SORRENTO THERAPEUTICS, INC: PRODUCT SEGMENTS
  • TABLE 114. SORRENTO THERAPEUTICS, INC: PRODUCT PORTFOLIO
  • TABLE 115. SORRENTO THERAPEUTICS, INC: KEY STRATERGIES
  • TABLE 116. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 117. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 118. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 119. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 120. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
  • TABLE 121. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
  • TABLE 122. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
  • TABLE 123. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
  • TABLE 124. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
  • TABLE 125. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 126. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 127. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 128. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 129. AUROBINDO PHARMA: KEY EXECUTIVES
  • TABLE 130. AUROBINDO PHARMA: COMPANY SNAPSHOT
  • TABLE 131. AUROBINDO PHARMA: PRODUCT SEGMENTS
  • TABLE 132. AUROBINDO PHARMA: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. SCIATICA TREATMENT MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF SCIATICA TREATMENT MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN SCIATICA TREATMENT MARKET (2022-2031)
  • FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALSCIATICA TREATMENT MARKET
  • FIGURE 10. SCIATICA TREATMENT MARKET, BY TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR ACUTE SCIATICA, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR CHRONIC SCIATICA, BY COUNTRY 2021-2031(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 14. SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY 2021-2031(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR STEROIDS, BY COUNTRY 2021-2031(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR ANTIDEPRESSANTS, BY COUNTRY 2021-2031(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 19. SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR RETAIL AND SPECIALTY PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021-2031(%)
  • FIGURE 23. SCIATICA TREATMENT MARKET BY REGION, 2021
  • FIGURE 24. U.S. SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. CANADA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. MEXICO SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. GERMANY SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. FRANCE SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. UK SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. ITALY SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. SPAIN SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. REST OF EUROPE SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. JAPAN SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. CHINA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. INDIA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. AUSTRALIA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. SOUTH KOREA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. REST OF ASIA-PACIFIC SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. BRAZIL SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. SAUDI ARABIA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. SOUTH AFRICA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. REST OF LAMEA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 47. COMPETITIVE DASHBOARD
  • FIGURE 48. COMPETITIVE HEATMAP: SCIATICA TREATMENT MARKET
  • FIGURE 49. TOP PLAYER POSITIONING, 2021
  • FIGURE 50. ABBOTT LABORATORIES: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 51. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 52. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 53. ALKEM LABORATORIES LTD: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 54. ALKEM LABORATORIES LTD: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 55. AMNEAL PHARMACEUTICALS LLC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 56. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 57. JOHNSON AND JOHNSON: SALES REVENUE, 2019-2021 ($MILLION)
  • FIGURE 58. JOHNSON AND JOHNSON: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 59. JOHNSON AND JOHNSON: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 60. SORRENTO THERAPEUTICS, INC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 61. SORRENTO THERAPEUTICS, INC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 62. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 63. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 64. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 65. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 66. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 67. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 68. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 69. AUROBINDO PHARMA: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 70. AUROBINDO PHARMA: REVENUE SHARE BY REGION, 2021 (%)
目次
Product Code: A13379

The sciatica treatment market size was valued for $678.02 million in 2021 and is estimated to reach $991.26 million by 2031, exhibiting a CAGR of 3.9% from 2022 to 2031.  

Sciatica is referred to the pain that mainly affects sciatic nerves whereas sciatic nerves are the nerves that travel from the lower back through the hips and buttocks and down through each leg. Sciatica usually affects only one side of the lower body but the pain can occur in any part of the nerve pathway from the lower back to the buttock and the back of a thigh and calf. Furthermore, common symptoms of sciatica include pain in the leg which may worsen when sitting, burning or tingling down the leg, shooting pain that makes it difficult for the person to stand. Moreover, the pain may also occur in foot and toes, depending on the part of sciatic nerve affected. Sciatica can be treated using various medications or analgesic drugs. The medications include anti-inflammatory drugs, analgesic drugs, anti-convulsant and others.  

Major factors that drive the growth of the sciatica treatment market include increase in incidence of sciatica, surge in R&D activities for developing novel therapeutics for sciatica and rise in awareness among the people regarding sciatica and its treatments. There is an increase in incidence of sciatica in the developing and developed countries which have many different causes. Sciatica is mainly caused due to herniated or slipped disk, degenerative disk, spinal stenosis, spondylolisthesis and others. According to the Johns Hopkins Arthritis Center, in the recent population estimates indicate that the prevalence of ankylosing spondylitis (AS) in the U.S. is approximately 0.2-0.5% and based on data from multiple countries, the age- and sex-adjusted incidence of ankylosing spondylitis (AS) is 0.4-14 per 100,000 people.  

In addition, in a year about 2% of people get a herniated disk. When a herniated disk happens to a vertebra in lower back, it can press on the sciatic nerve leading to sciatica. Thus, huge prevalence of such conditions leads to increase in incidences of sciatica. This, in turn, propels the growth of the sciatica treatment market. 

In addition, increase in R&D activities in pharmaceutical field is driving the growth of the market. Major players are focusing on developing new drugs and APIs having application in sciatica treatment that are potent and efficient. Moreover, there is an increase in outsourcing research activities by the pharmaceutical companies to academic and private contract research organizations (CROs), which allows the company to stay competitive and flexible in a world of increasingly advanced technologies. This supports the key market players to develop novel drug therapies for sciatica and other diseases, which further propels the growth of the market. 

Although, various key factors are driving the growth of the market, few factors such as lack of specific approved treatments for sciatica and presence of alternate treatment options hinder the growth of the market. Alternate treatment options including the physiotherapy, and bracing along with surgical treatment restrict the growth of the sciatica treatment market. However, emerging economies of Asia-Pacific and LAMEA present lucrative opportunities for market players for investments. For instance, countries such as China and India with huge population base and high patient pool offer lucrative opportunities for the market growth. 

The sciatica treatment market is segmented by type, treatment, distribution channel and region. By type, the market is categorized into acute sciatica, chronic sciatica and others. On the basis of drug class, the market is segregated into non-steroidal anti-inflammatory drug (NSAIDs), steroids, antidepressants, and others. On the basis of distribution channel, the market is categorized into hospital pharmacies, retail and specialty pharmacies and online providers.  

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

Major key players that operate in the Abbott, Alkem Laboratories Limited, Amneal Pharmaceuticals LLC., Aurobindo Pharma, Johnson & Johnson, Sinfonia Biotherapeutics, Sorrento Therapeutics, Inc, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited and Zydus Group.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the sciatica treatment market analysis from 2021 to 2031 to identify the prevailing sciatica treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the sciatica treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global sciatica treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Acute sciatica
  • Chronic sciatica
  • Others

By Drug class

  • Non-steroidal anti-inflammatory drugs
  • Steroids
  • Antidepressants
  • Others

By Distribution channel

  • Hospital pharmacies
  • Retail and specialty pharmacies
  • Online providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players

  • Abbott Laboratories
  • Teva Pharmaceutical Industries Limited
  • Aurobindo Pharma
  • Sorrento Therapeutics, Inc
  • Alkem Laboratories Ltd
  • Amneal Pharmaceuticals LLC
  • Johnson and Johnson
  • Sun Pharmaceutical Industries Ltd.
  • Sinfonia Biotherapeutics
  • Zydus Lifesciences Limited

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. High bargaining power of suppliers
    • 3.3.2. Moderate bargaining power of buyers
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate threat of new entrants
    • 3.3.5. Moderate intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in incidence of sciatica
      • 3.4.1.2. Increase in geriatric population
      • 3.4.1.3. Increase in R&D activities
    • 3.4.2. Restraints
      • 3.4.2.1. Presence of alternate treatment
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunity in emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: SCIATICA TREATMENT MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Acute sciatica
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Chronic sciatica
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: SCIATICA TREATMENT MARKET, BY DRUG CLASS

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Non-steroidal anti-inflammatory drugs
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Steroids
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Antidepressants
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Others
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Retail and specialty pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: SCIATICA TREATMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Drug class
    • 7.2.4. Market size and forecast, by Distribution channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Type
      • 7.2.5.1.3. Market size and forecast, by Drug class
      • 7.2.5.1.4. Market size and forecast, by Distribution channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Type
      • 7.2.5.2.3. Market size and forecast, by Drug class
      • 7.2.5.2.4. Market size and forecast, by Distribution channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Type
      • 7.2.5.3.3. Market size and forecast, by Drug class
      • 7.2.5.3.4. Market size and forecast, by Distribution channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Drug class
    • 7.3.4. Market size and forecast, by Distribution channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Type
      • 7.3.5.1.3. Market size and forecast, by Drug class
      • 7.3.5.1.4. Market size and forecast, by Distribution channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Type
      • 7.3.5.2.3. Market size and forecast, by Drug class
      • 7.3.5.2.4. Market size and forecast, by Distribution channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Type
      • 7.3.5.3.3. Market size and forecast, by Drug class
      • 7.3.5.3.4. Market size and forecast, by Distribution channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Type
      • 7.3.5.4.3. Market size and forecast, by Drug class
      • 7.3.5.4.4. Market size and forecast, by Distribution channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Type
      • 7.3.5.5.3. Market size and forecast, by Drug class
      • 7.3.5.5.4. Market size and forecast, by Distribution channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Type
      • 7.3.5.6.3. Market size and forecast, by Drug class
      • 7.3.5.6.4. Market size and forecast, by Distribution channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Drug class
    • 7.4.4. Market size and forecast, by Distribution channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Type
      • 7.4.5.1.3. Market size and forecast, by Drug class
      • 7.4.5.1.4. Market size and forecast, by Distribution channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Type
      • 7.4.5.2.3. Market size and forecast, by Drug class
      • 7.4.5.2.4. Market size and forecast, by Distribution channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Type
      • 7.4.5.3.3. Market size and forecast, by Drug class
      • 7.4.5.3.4. Market size and forecast, by Distribution channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Type
      • 7.4.5.4.3. Market size and forecast, by Drug class
      • 7.4.5.4.4. Market size and forecast, by Distribution channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Type
      • 7.4.5.5.3. Market size and forecast, by Drug class
      • 7.4.5.5.4. Market size and forecast, by Distribution channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Type
      • 7.4.5.6.3. Market size and forecast, by Drug class
      • 7.4.5.6.4. Market size and forecast, by Distribution channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Drug class
    • 7.5.4. Market size and forecast, by Distribution channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Type
      • 7.5.5.1.3. Market size and forecast, by Drug class
      • 7.5.5.1.4. Market size and forecast, by Distribution channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Type
      • 7.5.5.2.3. Market size and forecast, by Drug class
      • 7.5.5.2.4. Market size and forecast, by Distribution channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Type
      • 7.5.5.3.3. Market size and forecast, by Drug class
      • 7.5.5.3.4. Market size and forecast, by Distribution channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Type
      • 7.5.5.4.3. Market size and forecast, by Drug class
      • 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Abbott Laboratories
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Alkem Laboratories Ltd
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Amneal Pharmaceuticals LLC
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Johnson and Johnson
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Sinfonia Biotherapeutics
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Key strategic moves and developments
  • 9.6. Sorrento Therapeutics, Inc
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Sun Pharmaceutical Industries Ltd.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Zydus Lifesciences Limited
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Teva Pharmaceutical Industries Limited
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Aurobindo Pharma
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance